Full-Time

Senior Director

Research & Analytics, Biostatistics

Posted on 10/3/2025

Aetion

Aetion

51-200 employees

Real-world evidence software for life sciences

Compensation Overview

$205k - $225k/yr

Boston, MA, USA + 1 more

More locations: New York, NY, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
R
Git
Data Analysis
Requirements
  • PhD in biostatistics, statistics, or related quantitative field.
  • At least 5 years of relevant experience.
  • Extensive expertise in the design and conduct of descriptive, prediction, and causal inference observational/epidemiological studies using secondary sources of real-world data, such as administrative claims, electronic health records, and disease registries. Experience in the clinical trials space may meet this requirement.
  • Expertise in processing of raw real-world data files (especially from secondary sources) to obtain analysis-ready datasets, such as engaging with data from multiple tables, stringing data to create drug durations, applying complex algorithms (for example, creating pregnancy episodes), etc.
  • Proficiency in R programming language.
  • Proficiency in Github use.
  • Experience in people management, or cross-functional team management and decision making.
  • Excellent oral and written communication skills.
Responsibilities
  • Direct or matrixed management of a team of R programmers to ensure the timely delivery of robust analyses for Aetion’s real-world study portfolio, via rigorous code strategy, code review, and quality control review
  • Serve as an internal, client (and other stakeholder)-facing expert in statistical and/or epidemiologic methods to support the design and conduct of robust real-world research, including protocol and statistical analysis plan development and ensuring appropriateness of study design, sample size and statistical methodologies proposed
  • Autonomously conduct R programming, including data management, interpretation of results, and draft or review of sections relevant to the methods or results for reports or manuscripts
  • Support the identification, prioritization, design, and execution of methodological projects and staff training to ensure Aetion’s Science Team is equipped with best practices for robust real-world study design and conduct
  • Be active in external thought-leadership as aligned with Aetion’s strategic priorities, such as submission of conference abstracts, authorship of manuscripts, participation in regulatory events, workshops and webinars, etc.
  • Provide input on the appropriate application and prioritization of analytic product features and support their testing in collaboration with the Product Management and Engineering teams, based on use cases and input from clients and internal scientists.
  • Maintain knowledge base in statistical and/or epidemiologic methods as applied to observational (real-world) studies
  • Support and promote educational activities and knowledge sharing, including development of best practice documents
  • Mentor early-career programmers and biostatisticians/epidemiologists in R coding practices and quantitative methods
Desired Qualifications
  • Extensive expertise in the design and conduct of descriptive or inferential observational/epidemiological studies using secondary sources of real-world data to address.
  • Experienced in people management.
  • Experienced in strategic decision-making and leadership.

Aetion builds software that helps life sciences companies, regulators, and purchasers analyze real-world data to understand how medical interventions perform in real patient care. Its platform and apps manage longitudinal health data and can generate synthetic data using AI, enabling hypothesis testing, analysis, and ongoing safety monitoring, with additional data science and regulatory services. The solution emphasizes end-to-end real-world data workflows and rapid, ROI-focused insights that streamline decision-making. The goal is to maximize value from real-world data and speed informed decisions to improve patient care.

Company Size

51-200

Company Stage

Series C

Total Funding

$203.6M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Datavant acquisition completed July 2025 creates end-to-end RWE platform, doubling life sciences team and expanding addressable market.[1]
  • AWS Marketplace integration March 2025 removes procurement barriers and enables scalable cloud-based evidence generation for global customers.[2]
  • Barcelona technology hub doubled engineering capacity, developing Aetion Discover for visual-first exploratory analysis workflows.[3]

What critics are saying

  • Datavant integration erodes Aetion's standalone brand, driving client attrition to competitors like IQVIA within 6-12 months.[6]
  • FDA regulatory rejection of synthetic health data blocks life sciences revenue, forcing clients to compliant alternatives.[6]
  • Barcelona hub attrition after rapid scaling enables Komodo Health to outpace Aetion in rapid-cycle analytics capabilities.[6]

What makes Aetion unique

  • Aetion's rapid-cycle analytics technology uniquely transforms real-world clinical and financial data into regulatory-grade evidence quickly.[1][5]
  • Combined Datavant-Aetion ecosystem spans 300+ data partners across EHRs, claims, pharmacy, registries, and social determinants.[1]
  • Aetion's AI-driven platform automates hypothesis generation and analysis, accelerating insights from complex longitudinal datasets.[6]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision insurance

Free membership to OneMedical

FSA

4% 401(k) match

Commuter benefits for parking & transit

Unlimited PTO

Paid parental leave

Wellness stipend

Company activities

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

13%

2 year growth

10%
Business Wire
May 16th, 2025
Datavant to Acquire Aetion, Empowering Healthcare and Life Sciences Organizations to Generate High-Quality, Scalable Real-World Evidence from Connected, Privacy-Protected Data

Datavant, a leading health data platform company, today announced that it has signed an agreement to acquire Aetion, a leading real-world evidence (RWE) plat...

Endpoints News
May 15th, 2025
Exclusive: Datavant to acquire real-world data specialist Aetion, doubling life sciences team

Exclusive: Datavant to acquire real-world data specialist Aetion, doubling life sciences team.

Endpoints News
May 15th, 2025
Datavant Acquires Aetion, Expands Team

Datavant is acquiring Aetion, a competitor in the real-world data sector, as reported exclusively by Endpoints News. This acquisition will lead to Datavant doubling its life sciences team. Further details are expected to be announced by Datavant on Thursday.

PR Newswire
Mar 31st, 2025
Aetion Launches Aetion® Evidence Platform Availability In Aws Marketplace, Accelerating Real-World Evidence Benefits For Its Customers

Aetion's industry-leading platform integrates advanced analytics, scalable workflows and actionable insights empowering organizations to unlock the full potential of their data and achieve measurable impactNEW YORK, March 31, 2025 /PRNewswire/ -- Aetion , the global leader in real-world evidence (RWE) technology and analytics, today announced the availability of its Aetion® Evidence Platform (AEP) in Amazon Web Services (AWS) Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on AWS. This launch removes implementation barriers, simplifies procurement and enables life sciences organizations, payers and regulators to harness scalable, cloud-based evidence generation with the security and reliability of AWS.AEP empowers organizations to analyze real-world data (RWD) to generate transparent, reproducible and regulatory-grade evidence for decision-making in drug development, market access, policy and pricing. By leveraging AWS Marketplace, Aetion streamlines access to its platform and reliable, fit-for-purpose solutions tailored to meet each organization's specific objectives, as well as accelerating time-to-insights and ensuring compliance with global regulatory standards.Aetion relies on AWS as its core infrastructure, leveraging services such as Amazon Bedrock to power its artificial intelligence and machine learning (AI/ML)-driven capabilities in order to unlock hidden insights about patient populations and translate scientific intent to results. These technologies enhance AEP's ability to process complex RWD at scale, enabling sophisticated hypothesis generation and analysis automation for evidence generation."The availability of AEP in AWS Marketplace underscores our commitment to providing scalable, high-impact solutions that help organizations make real-world data work for them," said Jay Podence, senior vice president of Commercial Partnerships at Aetion. "By integrating with AWS, we offer our new and existing customers a seamless path to deploy and scale real-world evidence studies with enhanced efficiency and security. This is the first step in our vision to expand our collaboration with AWS to bring more value to our customers

株式会社PR TIMES
Feb 19th, 2025
NEC invests in Aetion for RWD/RWE collaboration

NEC's CVC fund, NEC Orchestrating Future Fund, has invested in Aetion, Inc., a U.S. company providing a medical data analysis platform. This investment aims to enhance collaboration in utilizing real-world data (RWD) and real-world evidence (RWE) for drug development. Aetion's platform, Aetion Evidence Platform, is used globally by pharmaceutical companies and healthcare organizations to improve decision-making. NEC and Aetion will explore synergies to streamline drug development processes.

INACTIVE